latest progress
recently, salubris announced that nmpa has accepted the marketing application of its self-developed sal0107.
sal0107 is an arb/ccb compound preparation for treating patients with primary hypertension with poor blood pressure control after allisartan or amlodipine mono-therapy.
after the launch of the product, it will form a strategic synergy with xinlitan (allisartan isoproxil tablets), a class 1.1 antihypertensive marketed drug, further enrich the innovative product pipeline in cardiovascular area, cover a broader population of hypertensive patients, provide patients with more medication options, and enhance the comprehensive competitiveness of salubris in the field of chronic disease.
basic information
drug name: sal0107
application information: registration and marketing authorization for domestically produced drugs
registry classification: 2.3 category
drug type: chemical
acceptance number: cxhs2200061
acceptance instructions: according to the provisions of article 32 of the administrative licensing law of the people's republic of china, it is decided to accept it after examination.